

BIOCON GROUP

FACT SHEET

September - 2014

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET	(Rs. Crores)	
	Sept 30, 2014	March 31, 2014
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	3,121	2,927
	3,221	3,027
Minority interest	62	82
Non-current liabilities		
(a) Long-term borrowings	783	606
(b) Deferred tax liability (net)	42	45
(c) Other long-term liabilities	580	603
(d) Long-term provisions	10	8
	1,415	1,262
Current liabilities		
(a) Short-term borrowings	400	244
(b) Trade payables	440	347
(c) Other current liabilities	485	612
(d) Short-term provisions	77	177
	1,402	1,380
TOTAL	6,100	5,751
ASSETS		
Non-current assets		
(a) Fixed assets	2,990	2,719
(b) Goodwill	179	12
(c) Non-current investments	65	65
(d) Long term loans and advances	298	269
(e) Other non-current assets	161	47
(f) Deferred tax asset	5	-
	3,698	3,112
Current assets		
(a) Current Investments	334	700
(b) Inventories	437	377
(c) Trade receivables	662	600
(d) Cash and cash equivalents	756	804
(e) Short term loans and advances	117	82
(f) Other current assets	96	76
	2,402	2,639
TOTAL	6,100	5,751

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	H1 FY 15	H1 FY 14	Variance
INCOME			
Biopharmaceuticals	1,103	1,086	2%
Biopharma *	877	886	-1%
Branded formulations - India	226	200	14%
Contract research	365	343	6%
Total Sales	1,468	1,429	3%
Other income	47	39	19%
Total Revenue	1,515	1,468	3%
EXPENDITURE			
Material & Power costs	685	678	1%
Staff costs	242	210	15%
Research & Development **	66	82	-19%
Other expenses	143	135	6%
Manufacturing, staff & other expenses	1,136	1,105	
EBITDA	379	363	5%
Interest & Finance charges	6	1	
Depreciation & Amortisation	106	98	8%
PBT	267	264	2%
Taxes	53	62	
NET PROFIT BEFORE MINORITY INTEREST	214	202	6%
Minority interest	9	6	
NET PROFIT FOR THE PERIOD	205	196	5%
EPS Rs.	10.3	9.8	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
Licensing Income	28	11	
<i>** Gross Research & Development expenses</i>			
	110	91	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 15	Q2 FY 14	Variance
<u>INCOME</u>			
Biopharmaceuticals	558	546	2%
Biopharma *	442	447	-1%
Branded formulations - India	116	99	17%
Contract research	192	188	2%
Total Sales	750	734	2%
Other income	23	19	24%
TOTAL REVENUE	773	753	3%
<u>EXPENDITURE</u>			
Material & Power costs	351	335	5%
Staff costs	125	103	22%
Research & Development **	35	39	-9%
Other expenses	74	88	-17%
Manufacturing, staff & other expenses	585	565	
EBITDA	188	188	-
Interest & Finance charges	5	-	
Depreciation & Amortisation	54	50	11%
PBT	129	138	-7%
Taxes	22	33	
NET PROFIT BEFORE MINORITY INTEREST	107	105	2%
Minority interest	5	3	
NET PROFIT FOR THE PERIOD	102	102	-
EPS Rs.	5.1	5.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	9	3	
** Gross Research & Development expenses	56	45	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 15	Q1 FY 15	Variance
<u>INCOME</u>			
Biopharmaceuticals	558	547	2%
Biopharma *	442	436	1%
Branded formulations - India	116	111	5%
Contract research	192	172	11%
Total Sales	750	719	4%
Other income	23	23	-1%
	773	742	4%
<u>EXPENDITURE</u>			
Material & Power costs	351	334	5%
Staff costs	125	116	8%
Research & Development **	35	31	13%
Other expenses	74	70	4%
Manufacturing, staff & other expenses	585	551	
EBITDA	188	191	-2%
Interest & Finance charges	5	1	
Depreciation & Amortisation	54	52	4%
PBT	129	138	-7%
Taxes	22	31	
NET PROFIT BEFORE MINORITY INTEREST	107	107	-
Minority interest	5	4	
NET PROFIT FOR THE PERIOD	102	103	-1%
EPS Rs.	5.1	5.2	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	9	19	
** Gross Research & Development expenses	56	54	